Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Melphalan at a dose of 200 mg/m(2) is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m(2) is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m(2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Auner, Holger W., Iacobelli, Simona, Sbianchi, Giulia, Knol-Bout, Cora, Blaise, Didier, Russell, Nigel H., Apperley, Jane F., Pohlreich, David, Browne, Paul V., Kobbe, Guido, Isaksson, Cecilia, Lenhoff, Stig, Scheid, Christof, Touzeau, Cyrille, Jantunen, Esa, Anagnostopoulos, Achilles, Yakoub-Agha, Ibrahim, Tanase, Alina, Schaap, Nicolaas, Wiktor-Jedrzejczak, Wieslaw, Krejci, Marta, Schönland, Stefan O., Morris, Curly, Garderet, Laurent, Kröger, Nicolaus
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5830386/
https://ncbi.nlm.nih.gov/pubmed/29217776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.181339
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars